{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:59:35Z","timestamp":1792807175038,"version":"4.5.0"},"reference-count":54,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CORTIS","award":["OPP1137034\/OPP1151915"],"award-info":[{"award-number":["OPP1137034\/OPP1151915"]}]},{"name":"The Bill and Melinda Gates Foundation (TB Modelling and Analysis Consortium)","award":["OPP1084276\/OPP1135288"],"award-info":[{"award-number":["OPP1084276\/OPP1135288"]}],"id":[{"id":"https:\/\/ror.org\/0456r8d26","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Vaccines","award":["OPP1160830"],"award-info":[{"award-number":["OPP1160830"]}]},{"name":"UNITAID","award":["4214-LSHTM-Sept15; PO 8477-0-600"],"award-info":[{"award-number":["4214-LSHTM-Sept15; PO 8477-0-600"]}],"id":[{"id":"https:\/\/ror.org\/05t99je22","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000269","name":"ESRC","doi-asserted-by":"publisher","award":["ES\/P008011\/1"],"award-info":[{"award-number":["ES\/P008011\/1"]}],"id":[{"id":"10.13039\/501100000269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Medical Research  Council (MRC) and the UK Department for International Development (DFID) under the MRC\/DFID Concordat agreement that is also part of the EDCTP2 programme supported by the European Union","award":["MR\/P002404\/1"],"award-info":[{"award-number":["MR\/P002404\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Optimal vaccine dosing is important to ensure the greatest protection and safety. Analysis of dose-response data, from previous studies, may inform future studies to determine the optimal dose. Implementing more quantitative modelling approaches in vaccine dose finding have been recently suggested to accelerate vaccine development. Adenoviral vectored vaccines are in advanced stage of development for a variety of prophylactic and therapeutic indications, however dose-response has not yet been systematically determined. To further inform adenoviral vectored vaccines dose identification, historical dose-response data should be systematically reviewed. A systematic literature review was conducted to collate and describe the available dose-response studies for adenovirus vectored vaccines. Of 2787 papers identified by Medline search strategy, 35 were found to conform to pre-defined criteria. The majority of studies were in mice or humans and studied adenovirus serotype 5. Dose-response data were available for 12 different immunological responses. The majority of papers evaluated three dose levels, only two evaluated more than five dose levels. The most common dosing range was 107\u20131010 viral particles in mouse studies and 108\u20131011 viral particles in human studies. Data were available on adenovirus vaccine dose-response, primarily on adenovirus serotype 5 backbones and in mice and humans. These data could be used for quantitative adenoviral vectored vaccine dose optimisation analysis.<\/jats:p>","DOI":"10.3390\/vaccines8010131","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T08:20:44Z","timestamp":1584519644000},"page":"131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route"],"prefix":"10.3390","volume":"8","author":[{"given":"Sara","family":"Afrough","sequence":"first","affiliation":[{"name":"Vaccitech Ltd., The Schrodinger Building, Heatley Road, The Oxford Science Park, Oxford OX4 4GE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[{"name":"Vaccitech Ltd., The Schrodinger Building, Heatley Road, The Oxford Science Park, Oxford OX4 4GE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-6635","authenticated-orcid":false,"given":"Richard","family":"White","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Benest","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4161\/hv.4.3.5318","article-title":"Novel vaccines and adjuvant systems: The utility of animal models for predicting immunogenicity in humans","volume":"4","author":"Davis","year":"2008","journal-title":"Hum. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Campi-Azevedo, A.C., de Almeida Estevam, P., Coelho-dos-Reis, J.G., Peruhype-Magalh\u00e3es, V., Villela-Rezende, G., Quaresma, P.F., de Lourdes Sousa Maia, M., Farias, R.H.G., Camacho, L.A.B., and da Silva Freire, M. (2014). Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-391"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Guerin, P.J., Naess, L.M., Fogg, C., Rosenqvist, E., Pinoges, L., Bajunirwe, F., Nabasumba, C., Borrow, R., Fr\u00f8holm, L.O., and Ghabri, S. (2008). Immunogenicity of fractional doses of tetravalent a\/c\/y\/w135 meningococcal polysaccharide vaccine: Results from a randomized non-inferiority controlled trial in Uganda. PLoS ONE Negl. Trop. Dis., 2.","DOI":"10.1371\/journal.pntd.0000342"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional Third and Fourth Dose of RTS,S\/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study","volume":"214","author":"Regules","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1016\/j.vaccine.2016.10.060","article-title":"The TB vaccine H56 + IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions","volume":"34","author":"Rhodes","year":"2016","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rhodes, S.J., Knight, G.M., Kirschner, D.E., White, R.G., and Evans, T.G. (2018). Dose finding for new vaccines: The role for immunostimulation\/immunodynamic modelling. arXiv.","DOI":"10.1016\/j.jtbi.2019.01.017"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-018-0075-3","article-title":"Using vaccine Immunostimulation\/Immunodynamic modelling methods to inform vaccine dose decision-making","volume":"3","author":"Rhodes","year":"2018","journal-title":"Npj Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rhodes, S.J., Sarfas, C., Knight, G.M., White, A., Pathan, A.A., McShane, H., Evans, T.G., Fletcher, H., Sharpe, S., and White, R.G. (2017). Using Data from Macaques to Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: A Proof-of-Concept Study of Immunostimulation\/Immunodynamic Modeling Methods. Clin. Vaccine Immunol., 24.","DOI":"10.1128\/CVI.00525-16"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jtbi.2019.01.017","article-title":"Dose finding for new vaccines: The role for immunostimulation\/immunodynamic modelling","volume":"465","author":"Rhodes","year":"2019","journal-title":"J. Theor. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Handel, A., Li, Y., McKay, B., Pawelek, K.A., Zarnitsyna, V., and Antia, R. (2018). Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS ONE Comput. Biol., 14.","DOI":"10.1101\/328559"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","article-title":"Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer\u2019s Construct, or Gene Inserts","volume":"5","author":"Sheets","year":"2008","journal-title":"J. Immunotoxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/bs.pmbts.2014.10.012","article-title":"Molecular Determinants of the Ratio of Inert to Infectious Virus Particles","volume":"129","author":"Klasse","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1128\/CVI.00587-14","article-title":"Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB\/c Mice","volume":"21","author":"Ondondo","year":"2014","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ou\u00e9draogo, A., Tiono, A.B., Kargougou, D., Yaro, J.B., Ou\u00e9draogo, E., Kabor\u00e9, Y., Kangoye, D., Bougouma, E.C., Gansane, A., and Henri, N. (2013). A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078679"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.virusres.2013.09.013","article-title":"Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time","volume":"178","author":"Vemula","year":"2013","journal-title":"Virus Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4161\/hv.26038","article-title":"Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults","volume":"9","author":"Creech","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_24","first-page":"2720","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.rvsc.2012.12.004","article-title":"Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice","volume":"94","author":"Zhou","year":"2013","journal-title":"Res. Vet. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zahn, R., Gillisen, G., Roos, A., Koning, M., van der Helm, E., Spek, D., Weijtens, M., Grazia Pau, M., Rado\u0161evi\u0107, K., and Weverling, G.J. (2012). Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044115"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Keefer, M.C., Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., and Fernandez, N. (2012). A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041936"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pandey, A., Singh, N., Vemula, S.V., Cou\u00ebtil, L., Katz, J.M., Donis, R., Sambhara, S., and Mittal, S.K. (2012). Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033428"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector","volume":"205","author":"Duncan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.1016\/j.vaccine.2011.08.085","article-title":"A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1128\/JVI.00928-10","article-title":"TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector","volume":"84","author":"Rhee","year":"2010","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Steitz, J., Barlow, P.G., Hossain, J., Kim, E., Okada, K., Kenniston, T., Rea, S., Donis, R.O., and Gambotto, A. (2010). A Candidate H1N1 Pandemic Influenza Vaccine Elicits Protective Immunity in Mice. PLoS ONE.","DOI":"10.1371\/journal.pone.0010492"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Richardson, J.S., Yao, M.K., Tran, K.N., Croyle, M.A., Strong, J.E., Feldmann, H., and Kobinger, G.P. (2009). Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005308"},{"key":"ref_35","first-page":"1268","article-title":"Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria","volume":"158","author":"Rodrigues","year":"1997","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.vaccine.2007.06.019","article-title":"Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant","volume":"25","author":"Ophorst","year":"2007","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques","volume":"80","author":"Capone","year":"2006","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/IAI.74.1.313-320.2006","article-title":"Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice","volume":"74","author":"Ophorst","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1128\/IAI.73.10.6885-6891.2005","article-title":"Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity","volume":"73","author":"Hashimoto","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_41","first-page":"6774","article-title":"Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers","volume":"171","author":"Pinto","year":"2003","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1099\/0022-1317-76-7-1583","article-title":"Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: Efficiency as virus vectors in the vaccination of permissive and non-permissive species","volume":"76","author":"Eloit","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Neilan, J.G., Schutta, C., Barrera, J., Pisano, M., Zsak, L., Hartwig, E., Rasmussen, M.V., Kamicker, B.J., Ettyreddy, D., and Brough, D.E. (2018). Efficacy of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine in cattle using a direct contact transmission model. BMC Vet. Res., 14.","DOI":"10.1186\/s12917-018-1582-1"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1080\/21645515.2017.1308988","article-title":"Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates","volume":"13","author":"Tang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1016\/j.vaccine.2017.04.062","article-title":"A prime-boost immunization regimen based on a Simian Adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice","volume":"35","author":"Fonseca","year":"2017","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38666","DOI":"10.1038\/srep38666","article-title":"Early life vaccination: Generation of adult-quality memory CD8+ T cells in infant mice using non-replicating adenoviral vectors","volume":"6","author":"Nazerai","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.vaccine.2016.08.048","article-title":"Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization","volume":"34","author":"Alayo","year":"2016","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Manzoli, L., Flacco, M.E., D\u2019Addario, M., Capasso, L., Vito, C.D., Marzuillo, C., Villari, P., and Ioannidis, J.P.A. (2014). Non-publication and delayed publication of randomized trials on vaccines: Survey. BMJ, 348.","DOI":"10.1136\/bmj.g3058"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2013.04.013","article-title":"A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results","volume":"192","author":"Gallaher","year":"2013","journal-title":"J. Virol. Methods"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional T H 1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat. Med."},{"key":"ref_54","first-page":"3494","article-title":"Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy","volume":"198","author":"Billeskov","year":"2017","journal-title":"J. Immunol. Baltim. Md 1950"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:26Z","timestamp":1760173646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["vaccines8010131"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8010131","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]}}}